EUR/USD
1.16106
-0.055%
Gold
4517.27
-0.568%
Oil
97.260
0.078%
USD/JPY
159.109
0.083%
GBP/USD
1.34216
-0.068%
GBP/JPY
213.538
0.018%
Real-time News
Germanys final first-quarter unadjusted GDP annual rate, Junes GfK consumer confidence index, and the UKs April seasonally adjusted retail sales month-on-month rate and public sector net borrowing will be released in ten minutes.European Commission Executive Vice President Dombrovskis: The EU will have to respond to soaring inflation.May 22nd, Futures News: Economies.com analysts latest view: Spot gold fell in the latest intraday trading, with a corrective bearish trend dominating in the short term. Furthermore, with prices trading below the 50-day EMA, negative pressure continues to strengthen, increasing downside risk. On the other hand, spot gold prices remain firmly above the key support level of $4500, showing strong positive momentum limiting the decline, especially after the overbought condition was digested. The Relative Strength Index (RSI) is showing a positive signal, providing more room for spot gold to show stronger positive performance in the short term.May 22nd, Futures News: Economies.com analysts latest view: WTI crude oil futures exhibited strong volatility in the latest intraday trading, with prices rising at one point in an attempt to recover some of the previous losses and restore some technical balance. This cautious rebound was mainly due to a slight easing of the clearly oversold condition shown by the Relative Strength Index (RSI), providing temporary support for the current price movement. Despite the limited improvement, negative pressure continues to dominate oil price movements. Previously, prices had broken below the upward channel that had been dominating its short-term trading. Furthermore, WTI crude oil futures remain below the 50-day EMA, continuing to face negative and dynamic pressure, which also increases the possibility of further declines in the short term.On May 22, UBS issued a research report stating that CSPC Pharmaceutical Group (01093.HK) is a pioneer in AI-driven drug discovery and development (AIDD) among leading pharmaceutical companies, and is the worlds largest AIDD platform licensor by total transaction value. The bank believes that CSPCs leading position in cutting-edge technologies such as AI has not yet been fully reflected in its valuation. With a series of licensing (BD) transactions finalized, the downside risks of its traditional business have been largely priced in, and the companys organic revenue (excluding licensing revenue) is expected to recover to 3.8% year-on-year growth in 2026 (compared to a 16.5% year-on-year decline last year). UBS upgraded CSPCs rating from Neutral to Buy, maintaining its target price of HK$10.9. UBS pointed out that CSPC has currently reached four licensing or collaboration agreements related to the AIDD platform, with a total transaction value of US$27.7 billion, making it the worlds largest AIDD platform licensor. The collaboration with AstraZeneca (AZN.O) is the most significant, validating the value of its AIDD platform. The bank expects the company to have several catalysts in the future, including the first quarter 2026 results to be announced on May 27, and the disclosure of clinical trial data for key R&D assets such as SYS6010 and KN026.
